Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 4/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14350403 | 0.78 | — | — | |
| SCHEMBL25505075 | 0.77 | HTR6 (0.35) | HTR6 | |
| SCHEMBL337087 | 0.71 | HTR6 (0.65) | HTR6TAAR1HTR2CHTR2B | |
| SCHEMBL26093433 | 0.71 | HTR6 (0.44) | HTR6TAAR1HTR2CHTR2B | |
| SCHEMBL29270116 | 0.69 | HTR6 (0.47) | HTR6HTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL6632484 | 0.69 | HTR6 (0.62) | HTR6TAAR1HTR2CHTR2B | |
| SCHEMBL1000577 | 0.68 | — | — | |
| SCHEMBL16529635 | 0.68 | — | — | |
| SCHEMBL3763667 | 0.68 | — | — | |
| SCHEMBL19316351 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663238-B1 | HEXA- AND OCTAHYDRO-PYRIDO[1,2-a] PYRAZINE DERIVATIVES WITH NK1 ANTAGONISTIC ACTIVITY | SOLVAY PHARM BV (NL) | 2009-08-12 | — | — | EP | disclosed |
| US-7244734-B2 | Hexa- and octahydro-pyrido[1,2-a]pyrazine derivatives with NK1 antagonistic activity | SOLVAY PHARMACEUTICALS B.V. (NL) | 2007-07-17 | — | — | US | disclosed |
| CN-1856309-A | Hexa- and octahydro-pyrido[1,2-a] pyrazine derivatives with NK1 antagonistic activity | SOLVAY PHARM BV (NL) | 2006-11-01 | — | — | CN | disclosed |
| EP-1663238-A1 | HEXA- AND OCTAHYDRO-PYRIDO[1,2-a] PYRAZINE DERIVATIVES WITH NK1 ANTAGONISTIC ACTIVITY | Solvay Pharmaceuticals B.V. (NL) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005030214-A1 | HEXA- AND OCTAHYDRO-PYRIDO[1,2-a]PYRAZINE DERIVATIVES WITH NK1 ANTAGONISTIC ACTIVITY | SOLVAY PHARMACEUTICALS B.V. (NL) | 2005-04-07 | — | — | WO | disclosed |
| US-20050070548-A1 | Hexa-and octahydro-pyrido[1,2-a]pyrazine derivatives with NK1 antagonistic activity | SOLVAY PHARMACEUTICALS B.V. | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070548-A1 | Hexa-and octahydro-pyrido[1,2-a]pyrazine derivatives with NK1 antagonistic activity | BDKRB2, TACR1, BDKRB1 | HTR6 137/4885TAAR1 188/4885HTR2C 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.